Cytorex EBV (baltaleucel-T) / Baylor College of Medicine, Houston Methodist Hospital, Texas Children’s Hospital, Athenex - LARVOL DELTA

Autologous EBV-Specific T Cells (CMD-003): Early Results from a Multicenter, Multinational Phase 2 Trial for Treatment of EBV-Associated NK/T-Cell Lymphoma (ASH 2017) - P2; "In the CITADEL trial, we have observed preliminary indications of activity and safety after administration of autologous EBV-specific T cells in patients with relapsed ENKTL. The clinical trial is ongoing and accruing patients."

P2 data • Biosimilar • Non-Hodgkin’s Lymphoma • Pain

Autologous Epstein-Barr virus (EBV)-specific T cells (baltaleucel T): preliminary results from a multicenter, multinational phase 2 study for treatment of EBV-associated NK/T cell lymphoma (SITC 2018) - P2; "Conclusions Our study demonstrates feasibility, clinical activity and safety of administration of single agent autologous EBV-specific T cells in patients with advanced, relapsed NKTL in a multicenter, multinational trial. These results require validation in a larger cohort."

Clinical • P2 data • Non-Hodgkin’s Lymphoma

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. (PubMed, Ann Hematol) - "We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL."

Clinical • Journal • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (clinicaltrials.gov) - P2; N=15; Terminated; Sponsor: Cell Medica Ltd; Recruiting ➔ Terminated; Trial primary completion date: Sep 2018 ➔ Apr 2018; N=35 ➔ 15; Trial completion date: Sep 2019 ➔ Sep 2018; Insufficient enrollment rate

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

CIVIC: Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (clinicaltrials.gov) - P2; N=1; Terminated; Sponsor: Cell Medica Ltd; N=70 ➔ 1; Trial completion date: Oct 2019 ➔ Feb 2018; Recruiting ➔ Terminated; Trial primary completion date: Dec 2018 ➔ Feb 2018; Insufficient recruitment rate

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination